<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01736059</url>
  </required_header>
  <id_info>
    <org_study_id>906595</org_study_id>
    <secondary_id>BMSCRetPilot</secondary_id>
    <nct_id>NCT01736059</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy</brief_title>
  <official_title>A Pilot Clinical Trial of the Feasibility and Safety of Intravitreal Autologous Adult Bone Marrow Stem Cells in Treating Eyes With Vision Loss From Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem
      cells from bone marrow into the eye as treatment for patients who are irreversibly blind from
      various retinal conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this pilot clinical trial, eyes with irreversible vision loss from retinal degenerative
      conditions (macular degeneration or retinitis pigmentosa) or retinal vascular disease
      (diabetic retinopathy or retinal vein occlusion) will be treated with intravitreal injection
      of autologous CD34+ stem cells isolated from bone marrow aspirate under Good Manufacturing
      Practice conditions. This study will determine whether there are any major safety and
      feasibility concerns using this therapy. Patients will be followed for 6 months after
      treatment by serial comprehensive eye examination supplemented with various retinal imaging
      and diagnostic tests.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of ocular adverse events</measure>
    <time_frame>1 day to 6 months</time_frame>
    <description>As evident on eye examination by severe decrease in vision and/or adverse effect requiring major treatment intervention directly attributable to study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of stem cells isolated and injected into the study eye</measure>
    <time_frame>1 day</time_frame>
    <description>Will determine the yield of the bone marrow aspiration and stem cell isolation procedures.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence and severity of systemic adverse events</measure>
    <time_frame>1 day to 6 months</time_frame>
    <description>Any systemic adverse event attributable to the bone marrow aspiration or intravitreal injection of the stem cells.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Non-exudative Age-related Macular Degeneration</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Retina Vein Occlusion</condition>
  <condition>Retinitis Pigmentosa</condition>
  <condition>Hereditary Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Stem cell treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD34+ bone marrow stem cells intravitreal</intervention_name>
    <arm_group_label>Stem cell treated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;18 years of age

          -  visual acuity 20/100 to CF

          -  duration of vision loss &gt; 3 months

          -  vision loss from macular degeneration, retinitis pigmentosa, retinal vein occlusion or
             diabetic retinopathy

          -  the study eye has the worse visual acuity

          -  no active eye or systemic disease

          -  no history of macular edema or retinal/choroidal neovascularization requiring
             treatment within 6 months

          -  no significant media opacity

          -  no coagulopathy or other hematologic abnormality

          -  no concurrent immunosuppressive therapy

          -  able to keep follow-up for 6 months

        Exclusion Criteria:

          -  allergy to fluorescein dye

          -  other concurrent retinal or optic nerve disease affecting vision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanna s Park, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California Davis Eye Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Park SS. Cell Therapy Applications for Retinal Vascular Diseases: Diabetic Retinopathy and Retinal Vein Occlusion. Invest Ophthalmol Vis Sci. 2016 Apr 1;57(5):ORSFj1-ORSFj10. doi: 10.1167/iovs.15-17594. Review.</citation>
    <PMID>27116667</PMID>
  </reference>
  <results_reference>
    <citation>Park SS, Bauer G, Abedi M, Pontow S, Panorgias A, Jonnal R, Zawadzki RJ, Werner JS, Nolta J. Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings. Invest Ophthalmol Vis Sci. 2014 Dec 9;56(1):81-9. doi: 10.1167/iovs.14-15415.</citation>
    <PMID>25491299</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2012</study_first_submitted>
  <study_first_submitted_qc>November 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stem cells</keyword>
  <keyword>intravitreal</keyword>
  <keyword>bone marrow CD34+ cells</keyword>
  <keyword>retinal disease</keyword>
  <keyword>clinical trial</keyword>
  <keyword>autologous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Once study is completed, the study findings will be published in peer reviewed publication for public access.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

